[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

JPH0217549B2 - - Google Patents

Info

Publication number
JPH0217549B2
JPH0217549B2 JP56032879A JP3287981A JPH0217549B2 JP H0217549 B2 JPH0217549 B2 JP H0217549B2 JP 56032879 A JP56032879 A JP 56032879A JP 3287981 A JP3287981 A JP 3287981A JP H0217549 B2 JPH0217549 B2 JP H0217549B2
Authority
JP
Japan
Prior art keywords
compound
reaction
group
general formula
lower alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP56032879A
Other languages
Japanese (ja)
Other versions
JPS57146772A (en
Inventor
Shoichi Kakehi
Suketaka Ito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Priority to JP56032879A priority Critical patent/JPS57146772A/en
Publication of JPS57146772A publication Critical patent/JPS57146772A/en
Publication of JPH0217549B2 publication Critical patent/JPH0217549B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Description

【発明の詳細な説明】[Detailed description of the invention]

本発明は新規な3,3−ジ置換インドリジン−
2−オン化合物に関する。 本発明者らは、かねてより特定のピリジニウム
化合物を出発原料として得られる一連のインドリ
ジン−2−オン誘導体につき種々研究を重ねてき
たが、その過程において、下記反応行程式に示す
ように、原料とするピリジニウム化合物に塩基性
化合物を作用させて得られる2,3−ジヒドロイ
ンドリジン−2−オン類と、特定のオレフイン化
合物とが容易に反応するという事実及び上記反応
によつて文献未載の3,3−ジ置換インドリジン
−2−オン化合物が収得できるという事実を見い
出した。本発明はかかる新しい知見に基づいて完
成されたものである。 本発明の3,3−ジ置換インドリジン−2−オ
ン化合物は、下記一般式()で表わされる。 (式中Rは水素原子、低級アルキル基、フエニ
ル基またはハロゲン置換フエニル基を、R1は水
素原子または低級アルキル基を、R3は水素原子
または低級アルキル基を、R4はシアノ基または
カルバモイル基を意味する) 上記一般式()で表わされる通り本発明化合
物は、R3が水素原子以外を示す場場合には不斉
炭素に基づく立体異性体を包含する。 上記一般式()中R,R1及びR3で定義され
る低級アルキル基としては、炭素数1〜6のアル
キル基例えばメチル、エチル、プロピル、ブチ
ル、ヘキシル基等を例示できる。ハロゲン原子と
しては、塩素、臭素、沃素原子等を例示できる。 上記一般式()で示される本発明化合物は、
抗アレルギー作用、血小板凝集抑制作用、抗菌作
用等を有し、医薬品分野において抗アレルギー
剤、抗血栓剤、抗菌剤等として有用である。 以下本発明化合物の製造法につき説明する。本
発明化合物は例えば下記反応行程式に示す方法に
従い製造される。 <反応行程式> (各式中R,R1,R3及びR4は前記に同じ。R2
は低級アルキル基を、Xはハロゲン原子を意味す
る) 即ち本発明化合物は上記一般式()で示され
るピリジニウム化合物に塩基性化合物を作用させ
ると共に一般式()で示されるオレフイン化合
物を反応させることにより製造される。 上記において原料として使用されるピリジニウ
ム化合物()は公知の化合物であり、たとえば
ジヤーナル・オブ・オーガニツク・ケミストリー
(J.Org.Chem.)36,2451(1971)に記載の方法ま
たはこれに準ずる方法により容易に合成すること
ができる。また塩基性化合物としては、たとえば
水酸化ナトリウム、水酸化カリウム等の水酸化ア
ルカリ金属、水酸化カルシウム、水酸化マグネシ
ウム等の水酸化アルカリ土類金属、炭酸水素ナト
リウム、炭酸水素カリウム等の炭酸水素アルカリ
金属、炭酸ナトリウム、炭酸カリウム等の炭酸ア
ルカリ金属、炭酸カルシウム、炭酸マグネシウム
等の炭酸アルカリ土類金属、水素化リチウム、水
素化ナトリウム、水素化カリウム等の水素化アル
カリ金属、ナトリウムメトキシド、ナトリウムエ
トキシド、カリウムブトキシド等の金属アルコキ
シド等の無機塩基性化合物の他ピリジン、ピコリ
ン、トリエチルアミン、N−メチルピペリジン等
の有機塩基性化合物が挙げられる。塩基性化合物
の使用量は適宜選択することができるが、一般に
ピリジニウム化合物()に対して1〜2当量程
度使用するのが有利である。上記ピリジニウム化
合物()と塩基性化合物との反応は通常溶媒中
で行なわれる。溶媒は不活性な溶媒であれば特に
限定されないが、たとえばメタノール、エタノー
ル、プロパノール等の低級アルコール類、エーテ
ル、テトラヒドロフラン、ジオキサン等のエーテ
ル類、ベンゼン、トルエン、キシレン等の芳香族
炭化水素類、クロロホルム、塩化メチレン、、四
塩化炭素等のハロゲン化炭化水素類、ジメチルス
ルホキシド、ジメチルホルムアミド等の中から使
用するピリジニウム化合物()および塩基性化
合物の種類により適宜選択して使用される。反応
温度は特に限定されないが、通常室温〜50℃付近
で行なうと反応は有利に進行する。 上記の反応により一般式()で示されるジヒ
ドロインドリジン−2−オン化合物()が生成
する。これは通常の方法により反応系より単離可
能であるが、本発明では特にこのジヒドロインド
リジン−2−オン化合物()を単離することな
く、引き続き反応系内に一般式()で示される
オレフイン化合物()を導入して反応させるこ
とができる。勿論上記化合物()を単離し、別
個にこれとオレフイン化合物()とを反応させ
ることもでき、また適当な容器にピリジニウム化
合物()、塩基性化合物及びオレフイン化合物
()を同時に仕込んでも略々同様に目的とする
反応は進行し得る。いずれの場合も、オレフイン
化合物()の使用量は通常ピリジニウム化合物
()に対して2〜5モル程度とするのが有利で
ある。上記化合物()と化合物()との反応
温度は特に限定されないが、一般に室温〜100℃
程度で行なうのが有利である。本反応で生成する
3,3−ジ置換インドリジン−2−オン化合物
()は通常の分離手段例えば再結晶法、カラム
クロマトグラフイー等により容易に単離可能であ
る。 以下本発明の一般式()で表わされる3,3
−ジ置換インドリジン−2−オン化合物の代表例
を挙げ、次いで之等各化合物の製造例を実施例と
して挙げる。
The present invention provides novel 3,3-disubstituted indolizine-
Relating to 2-one compounds. The present inventors have long conducted various studies on a series of indolizin-2-one derivatives obtained using a specific pyridinium compound as a starting material. The fact that 2,3-dihydroindolizin-2-ones, which are obtained by reacting a basic compound with a pyridinium compound, easily reacts with a specific olefin compound, and the above-mentioned reaction results in the discovery of an unpublished literature. It has been discovered that 3,3-disubstituted indolizin-2-one compounds can be obtained. The present invention was completed based on this new knowledge. The 3,3-disubstituted indolizin-2-one compound of the present invention is represented by the following general formula (). (In the formula, R is a hydrogen atom, a lower alkyl group, a phenyl group, or a halogen-substituted phenyl group, R 1 is a hydrogen atom or a lower alkyl group, R 3 is a hydrogen atom or a lower alkyl group, and R 4 is a cyano group or a carbamoyl group. As represented by the above general formula (), the compounds of the present invention include stereoisomers based on asymmetric carbon atoms when R 3 is other than a hydrogen atom. Examples of the lower alkyl group defined by R, R 1 and R 3 in the above general formula () include alkyl groups having 1 to 6 carbon atoms, such as methyl, ethyl, propyl, butyl, and hexyl groups. Examples of the halogen atom include chlorine, bromine, and iodine atoms. The compound of the present invention represented by the above general formula () is:
It has antiallergic effects, platelet aggregation inhibitory effects, antibacterial effects, etc., and is useful as an antiallergic agent, antithrombotic agent, antibacterial agent, etc. in the pharmaceutical field. The method for producing the compound of the present invention will be explained below. The compound of the present invention can be produced, for example, according to the method shown in the following reaction scheme. <Reaction equation> (In each formula, R, R 1 , R 3 and R 4 are the same as above. R 2
represents a lower alkyl group, and X represents a halogen atom) In other words, the compound of the present invention can be obtained by reacting a pyridinium compound represented by the above general formula () with a basic compound and an olefin compound represented by the general formula (). Manufactured by. The pyridinium compound () used as a raw material in the above is a known compound, for example, by the method described in Journal of Organic Chemistry (J.Org.Chem.) 36, 2451 (1971) or a method analogous thereto. Can be easily synthesized. Examples of basic compounds include alkali metal hydroxides such as sodium hydroxide and potassium hydroxide, alkaline earth metal hydroxides such as calcium hydroxide and magnesium hydroxide, and alkali hydrogen carbonates such as sodium hydrogen carbonate and potassium hydrogen carbonate. Metals, alkali metal carbonates such as sodium carbonate and potassium carbonate, alkaline earth metal carbonates such as calcium carbonate and magnesium carbonate, alkali metal hydrides such as lithium hydride, sodium hydride and potassium hydride, sodium methoxide, sodium ethoxy In addition to inorganic basic compounds such as metal alkoxides such as carbon dioxide, potassium butoxide, etc., organic basic compounds such as pyridine, picoline, triethylamine, and N-methylpiperidine can be mentioned. The amount of the basic compound to be used can be selected as appropriate, but it is generally advantageous to use about 1 to 2 equivalents relative to the pyridinium compound (). The reaction between the pyridinium compound () and the basic compound is usually carried out in a solvent. The solvent is not particularly limited as long as it is an inert solvent, but examples include lower alcohols such as methanol, ethanol, and propanol, ethers such as ether, tetrahydrofuran, and dioxane, aromatic hydrocarbons such as benzene, toluene, and xylene, and chloroform. , methylene chloride, halogenated hydrocarbons such as carbon tetrachloride, dimethyl sulfoxide, dimethyl formamide, etc., depending on the type of pyridinium compound () and basic compound used. Although the reaction temperature is not particularly limited, the reaction usually proceeds advantageously at room temperature to around 50°C. The above reaction produces a dihydroindolizin-2-one compound () represented by the general formula (). This can be isolated from the reaction system by a conventional method, but in the present invention, the dihydroindolizin-2-one compound () is not isolated, but the dihydroindolizin-2-one compound () is subsequently added to the reaction system as shown by the general formula (). An olefin compound () can be introduced and reacted. Of course, it is also possible to isolate the above compound () and react it with the olefin compound () separately, or it is also possible to simultaneously charge the pyridinium compound (), the basic compound, and the olefin compound () in a suitable container to achieve almost the same result. The desired reaction can proceed. In either case, it is advantageous that the amount of the olefin compound () to be used is usually about 2 to 5 moles relative to the pyridinium compound (). The reaction temperature between the above compound () and compound () is not particularly limited, but is generally room temperature to 100°C.
It is advantageous to do this in moderation. The 3,3-disubstituted indolizin-2-one compound () produced in this reaction can be easily isolated by conventional separation methods such as recrystallization, column chromatography, etc. 3,3 represented by the general formula () of the present invention below:
Representative examples of -disubstituted indolizin-2-one compounds will be given, and then examples of the production of these compounds will be given as examples.

【表】【table】

【表】【table】

【表】【table】

【表】【table】

【表】【table】

【表】 実施例 1 2−ベンジル−1−(エトキシカルボニルメチ
ル)ピリジニウムブロミド1.01g(3ミリモル)
のエタノール溶液(40ml)に水酸化カリウム水溶
液(85%水酸化カリウム0.3gと水0.5ml)を加
え、室温で10分攬拌した後、メタクリル酸エチル
1.03g(9ミリモル)を加える。このまま1時間
攬拌した後、反応溶液を過して不溶物を除き、
液を濃縮する。残渣をエーテル、次いでクロロ
ホルムを溶媒としてアルミナカラムを用いて分離
した後、クロロホルム−ヘキサンより再結晶し
て、融点101〜102℃の3,3−ビス(2−エトキ
シカルボニルプロピル)−1−フエニル−2.3−ジ
ヒドロインドリジン−2−オン(化合物No.19)
1.05gを得た(収率80%)。 実施例1と同様の方法により、化合物No.9,10
および15を合成した。 実施例 2 1−(エトキシカルボニルメチル)−2−プロピ
ルピリジニウムブロミド0.86g(3ミリモル)の
エタノール溶液に炭酸カリウム10gを加え、室温
で2時間攬拌した後、アクリロニトリル0.48g
(9ミリモル)を加え、さらに3時間攬拌する。
反応溶液を過して不溶物を除き、液を濃縮す
る。残渣をクロロホルムを溶媒としてアルミナカ
ラムで分離した後、クロロホルム−ヘキサンから
再結晶して融点138〜140℃の3,3−ビス(2−
シアノエチル)1−エチル−2,3−ジヒドロイ
ンドリジン−2−オン(化合物No.2)0.43gを得
た(収率54%)。 実施例2と同様の方法により、化合物No.6,
7,8,13,16(16a及び16b),17および20を合
成した。 尚、化合物No.16の合成について、更に詳述す
る。 1−(エトキシカルボニルメチル)−2−(p−
クロルベンジル)ピリジニウムブロミド1.11g
(3ミリモル)のエタノール溶液に炭酸カリウム
10gを加え、室温で2時間攬拌した後、メタクリ
ロニトリル0.60g(9ミリモル)を加え、さらに
3時間攬拌した。反応溶液を過して不溶物を除
き、液を濃縮した。残渣をクロロホルムを溶媒
としてアルミナカラムで分離すると、初めに化合
物16aの分画が、次いで化合物16bの分画が溶出
した。これらをクロロホルム−ヘキサンから再結
晶して3,3−ビス(2−シアノプロピル)−1
−(p−クロロフエニル)−2,3−ジヒドロイン
ドリジン−2−オンのジアステレオマーである融
点226〜227℃の化合物16a0.25g(収率22%)と
融点203〜204℃の化合物16b0.48g(収率42%)
を得た。 NMR(CDCl3),δ(ppm): 16a1.33(6H,d,J=7.0Hz,CH3×2) 2.0−2.6(6H,m,1′,1″,2′,2″−H) 6.78(1H,m,6−H) 7.4−7.9(7H,m,フエニル環上−H,5,
7,8−H) 16b1.28(3H,d,J=7.0Hz,CH3) 1.33(3H,d,J=7.0Hz,CH3) 1.9−3.3(6H,m,1′,1″,2′,2″−H) 6.75(1H,m,6−H) 7.4−7.9(7H,m,フエニル環上−H,5,
7,8−H) IR(KBr.cm-1: 16a2241(CN),1605(C=O),1510,1482, 1291,1143,830,759 16b2235(CN),1603(C=O),1508,1480, 1285,1139,828,754 化合物No.16aと16bとを比較すると、これらは
立体配置において、構造の違いがあることが判
る。 即ち、両者のIRは非常に良く似ているが、
NMRについては下線部のメチル基が16aでは1
種だけ、16bでは、2種現れており、16aは対称
要素を有する光学不活性なジアステレオマーであ
り、16bは光学活性なジアステレオマーのd混
合物であると考えられる。 実施例 3 1−(エトキシカルボニルメチル)−2−エチル
ピリジニウムブロミド1.37g(5ミリモル)のエ
タノール溶液(70ml)にナトリウムエトキシド−
エタノール溶液(ナトリウムエトキシド5ミリモ
ルを含むエタノール5ml溶液)を加え、室温で10
分攬拌した後、アクリロニトリル0.80(15ミリモ
ル)を加え、さらに1時間攬拌する。この反応溶
液を希塩酸を用いて中和した後、不溶物を過し
て除く、液を濃縮し、残渣をクロロホルムを溶
媒としてアルミナカラムを用いて分離した後、ク
ロロホルム−エーテルより再結晶して融点74〜75
℃の3,3−ビス(2−シアノエチル)−1−メ
チル−2,3−ジヒドロインドリジン−2−オン
(化合物No.1)0.85gを得た(収率63%)。 実施例3と同様の方法により、化合物No.3,
4,5,11,12,14および18を合成した。
[Table] Example 1 2-benzyl-1-(ethoxycarbonylmethyl)pyridinium bromide 1.01g (3 mmol)
Add a potassium hydroxide aqueous solution (0.3 g of 85% potassium hydroxide and 0.5 ml of water) to an ethanol solution (40 ml), stir at room temperature for 10 minutes, and add ethyl methacrylate.
Add 1.03g (9 mmol). After stirring for 1 hour, the reaction solution was filtered to remove insoluble matter.
Concentrate the liquid. The residue was separated using an alumina column using ether and then chloroform as a solvent, and then recrystallized from chloroform-hexane to give 3,3-bis(2-ethoxycarbonylpropyl)-1-phenyl- with a melting point of 101-102°C. 2.3-dihydroindolizin-2-one (compound No. 19)
1.05g was obtained (yield 80%). Compounds No. 9 and 10 were prepared in the same manner as in Example 1.
and 15 were synthesized. Example 2 10 g of potassium carbonate was added to an ethanol solution of 0.86 g (3 mmol) of 1-(ethoxycarbonylmethyl)-2-propylpyridinium bromide, and after stirring at room temperature for 2 hours, 0.48 g of acrylonitrile was added.
(9 mmol) and stirred for an additional 3 hours.
The reaction solution is filtered to remove insoluble matter, and the liquid is concentrated. The residue was separated on an alumina column using chloroform as a solvent, and then recrystallized from chloroform-hexane to give 3,3-bis(2-
0.43 g of (cyanoethyl)1-ethyl-2,3-dihydroindolizin-2-one (compound No. 2) was obtained (yield 54%). Compound No. 6,
7, 8, 13, 16 (16a and 16b), 17 and 20 were synthesized. The synthesis of compound No. 16 will be described in further detail. 1-(ethoxycarbonylmethyl)-2-(p-
Chlorbenzyl) pyridinium bromide 1.11g
Potassium carbonate (3 mmol) in ethanol solution
After adding 10 g of the mixture and stirring at room temperature for 2 hours, 0.60 g (9 mmol) of methacrylonitrile was added and stirring was further continued for 3 hours. The reaction solution was filtered to remove insoluble matter, and the solution was concentrated. When the residue was separated on an alumina column using chloroform as a solvent, a fraction of compound 16a was eluted first, and then a fraction of compound 16b was eluted. These were recrystallized from chloroform-hexane to give 3,3-bis(2-cyanopropyl)-1
Compound 16a, a diastereomer of -(p-chlorophenyl)-2,3-dihydroindolizin-2-one, with a melting point of 226-227°C (yield 22%), and compound 16b0 with a melting point of 203-204°C. 48g (yield 42%)
I got it. NMR (CDCl 3 ), δ (ppm): 16a1.33 (6H, d, J = 7.0Hz, CH 3 × 2) 2.0−2.6 (6H, m, 1′, 1″, 2′, 2″−H ) 6.78 (1H, m, 6-H) 7.4-7.9 (7H, m, -H on phenyl ring, 5,
7,8-H) 16b1.28 (3H, d, J=7.0Hz, CH 3 ) 1.33 (3H, d, J=7.0Hz, CH 3 ) 1.9-3.3 (6H, m, 1′, 1″, 2′, 2″-H) 6.75 (1H, m, 6-H) 7.4-7.9 (7H, m, phenyl ring-H, 5,
7,8-H) IR (KBr.cm -1 : 16a2241(CN), 1605(C=O), 1510, 1482, 1291, 1143, 830, 759 16b2235(CN), 1603(C=O), 1508 , 1480, 1285, 1139, 828, 754 Comparing Compounds No. 16a and 16b, it can be seen that they have structural differences in steric configuration. In other words, their IRs are very similar, but
Regarding NMR, the underlined methyl group is 1 in 16a.
Two species appear in 16b; 16a is an optically inactive diastereomer with a symmetry element, and 16b is considered to be a mixture of optically active diastereomers. Example 3 Sodium ethoxide was added to an ethanol solution (70 ml) of 1.37 g (5 mmol) of 1-(ethoxycarbonylmethyl)-2-ethylpyridinium bromide.
Add ethanol solution (5 ml of ethanol solution containing 5 mmol of sodium ethoxide) and incubate for 10 minutes at room temperature.
After stirring, add 0.80 (15 mmol) of acrylonitrile and stir for an additional hour. After neutralizing this reaction solution using diluted hydrochloric acid, insoluble matter was removed by filtration, the liquid was concentrated, the residue was separated using an alumina column using chloroform as a solvent, and then recrystallized from chloroform-ether to obtain the melting point. 74-75
0.85 g of 3,3-bis(2-cyanoethyl)-1-methyl-2,3-dihydroindolizin-2-one (compound No. 1) was obtained (yield: 63%). By the same method as in Example 3, compound No. 3,
4, 5, 11, 12, 14 and 18 were synthesized.

Claims (1)

【特許請求の範囲】 1 一般式 (式中Rは水素原子、低級アルキル基、フエニ
ル基またはハロゲン置換フエニル基を、R1は水
素原子または低級アルキル基を、R3は水素原子
または低級アルキル基を、R4はシアノ基または
カルバモイル基を意味する) で示される3,3−ジ置換インドリジン−2−オ
ン化合物。
[Claims] 1. General formula (In the formula, R is a hydrogen atom, a lower alkyl group, a phenyl group, or a halogen-substituted phenyl group, R 1 is a hydrogen atom or a lower alkyl group, R 3 is a hydrogen atom or a lower alkyl group, and R 4 is a cyano group or a carbamoyl group. A 3,3-disubstituted indolizin-2-one compound represented by:
JP56032879A 1981-03-06 1981-03-06 3,3-di-substituted indolidin-2-one compound and its preparation Granted JPS57146772A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP56032879A JPS57146772A (en) 1981-03-06 1981-03-06 3,3-di-substituted indolidin-2-one compound and its preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP56032879A JPS57146772A (en) 1981-03-06 1981-03-06 3,3-di-substituted indolidin-2-one compound and its preparation

Publications (2)

Publication Number Publication Date
JPS57146772A JPS57146772A (en) 1982-09-10
JPH0217549B2 true JPH0217549B2 (en) 1990-04-20

Family

ID=12371156

Family Applications (1)

Application Number Title Priority Date Filing Date
JP56032879A Granted JPS57146772A (en) 1981-03-06 1981-03-06 3,3-di-substituted indolidin-2-one compound and its preparation

Country Status (1)

Country Link
JP (1) JPS57146772A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4480106A (en) * 1981-10-28 1984-10-30 Ciba-Geigy Corporation Process for the preparation of asymmetrically substituted maleic anhydrides, and asymmetrically substituted maleic anhydrides
US4567270A (en) * 1984-09-17 1986-01-28 G. D. Searle & Co. Hexahydroindolizinones useful for treating cardiac arrhythmia, thrombotic disorders in mammals

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56127376A (en) * 1980-03-10 1981-10-06 Taiho Yakuhin Kogyo Kk Indolizine-2-one derivative and its preparation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56127376A (en) * 1980-03-10 1981-10-06 Taiho Yakuhin Kogyo Kk Indolizine-2-one derivative and its preparation

Also Published As

Publication number Publication date
JPS57146772A (en) 1982-09-10

Similar Documents

Publication Publication Date Title
EP3862347A1 (en) Processes for their preparation of 5-fluoro-4-imino-3-(alkyl/substituted alkyl)-1-(arylsulfonyl)- 3,4-dihydropyrimidin-2(1h)-one
JP2001055379A (en) Production of 1-methyl-1,2,3,4-tetrahydroisoquinoline
SU474981A3 (en) The method of obtaining 9 (1-substituted-4piperidylidene) -thioxanthenes or their salts
NO861988L (en) INTERMEDIATES FOR THE PREPARATION OF NEW SUBSTITUTED HETEROCYCLIC PHENOXYAMINES AND PROCEDURES FOR THE PREPARATION OF THEREOF.
US12071399B2 (en) Process for the preparation of arylsulfonylpropenenitriles
GB2101986A (en) Thiazolinoazetidinone derivatives
JPH0217549B2 (en)
JP4994772B2 (en) Method for producing piperidin-4-one derivative using bisaminol ether compound
GB1594450A (en) 1,3-oxathiolane sulphoxides and their use in the preparation of 5,6-dihydro-2-methyl-1,4-oxathiin derivatives
US4150043A (en) 0-(2,3-Epoxypropyl)-hydroximic acid esters
JP2659587B2 (en) 4-aziridinyl pyrimidine derivatives and their production
JPH0217550B2 (en)
MXPA02001248A (en) Process for the preparation of acylated 1,3-dicarbonyl compounds.
JPS6228149B2 (en)
JP3252484B2 (en) Method for producing 4,5-dihydro [1,2,4] triazolo [4,3-a] quinoxaline derivative
JP3716435B2 (en) Process for producing 2-substituted-5-chloroimidazole-4-carbaldehyde
JPH0219117B2 (en)
JPH0220638B2 (en)
US3864330A (en) Benzodiazepine derivatives and production thereof
HU198179B (en) Process for producing n-methyl-1-alkylthio-2-nitroethenamine derivatives
US5239092A (en) Process for producing furylpropargylcarbinol and derivative thereof
JP4055246B2 (en) 5-chloro-6- (α-fluoroalkyl) -4-pyrimidone and process for producing the same
KR800001048B1 (en) Process for preparing-4-hydroxy methyl-2-pyrroli-dinones
JPH06228103A (en) New octahydroacridine derivative and its production
JPS6159309B2 (en)